

Web appendix 2: List of included studies

1. Alkim H, Iscan M, Oz F. Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of *Helicobacter pylori* in Turkey. *Libyan J Med* 2011;6.
2. Aminian K, Farsad F, Ghanbari A, Fakhreih S, Hasheminasab SM. A randomized trial comparing four *Helicobacter pylori* eradication regimens: standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy. *Trop Gastroenterol* 2010;31:303-7.
3. Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for *Helicobacter pylori* eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. *Eur J Intern Med* 2010;21:310-4.
4. Avşar E, Tiftikçi A, Poturoğlu S, et al. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole based triple therapy for the eradication of *Helicobacter pylori* in dyspeptic patients. *Turk J Gastroenterol* 2013;24:316-21.
5. Aydin A, Onder G, Akarca U, Tekin F, Tuncyurek M, Ilter T. Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases. *Eur J Intern Med* 2007;18:496-500.
6. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of *Helicobacter pylori*. *Am J Gastroenterol* 2011;106:1970-5.
7. Bekar O, Yilmaz Y, Gulden M. Kefir improves the efficacy and tolerability of triple therapy in eradicating *Helicobacter pylori*. *J Med Food* 2011;14:344-7.
8. Bhasin DK, Sharma BC, Ray P, Pathak CM, Singh K. Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of *Helicobacter pylori*: a report from India. *Helicobacter* 2000;5:84-7.
9. Bujanda L, Herrerías JM, Ripollés V, et al. Efficacy and tolerability of three regimens for *Helicobacter pylori* eradication. A multicentre, double-blind, randomised clinical trial. *Clin Drug Invest* 2001;21:1-7.
10. Bujanda L, Sánchez A, Iriondo C, Santos A, Cosme A, Muñoz C. Comparative study of the eradication of *Helicobacter pylori*: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days. *An Med Interna* 2001;18:361-3.
11. Calvet X, Ducons J, Bujanda L, et al. Seven versus ten days of rabeprazole triple therapy for *Helicobacter pylori* eradication: a multicenter randomized trial. *Am J Gastroenterol* 2005;100:1696-701.
12. Calvet X, Ducons J, Guardiola J, et al. One-week triple vs. quadruple therapy for *Helicobacter pylori* infection - a randomized trial. *Aliment Pharmacol Ther* 2002;16:1261-7.
13. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of *Lactobacillus acidophilus* increases *Helicobacter pylori* eradication rates. *Aliment Pharmacol Ther* 2000;14:1625-9.
14. Catalano F, Branciforte G, Catanzaro R, Cipolla R, Bentivegna C, Brogna A. *Helicobacter pylori*-positive duodenal ulcer: three-day antibiotic eradication regimen. *Aliment Pharmacol Ther* 2000;14:1329-34.
15. Catalano F, Catanzaro R, Bentivegna C, Brogna A, Condorelli G, Cipolla R. Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of *Helicobacter pylori* and healing of duodenal ulcer. *Aliment Pharmacol Ther* 1998;12:59-62.

16. Chen LW, Chien RN, Chang JJ, Fang KM, Chang LC. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line *Helicobacter pylori* eradication: a prospective randomised study. *Int J Clin Pract* 2010;64:1530-4.
17. Cheng H, Hu FL, Zhang GX, et al. Levofloxacin-based triple therapy for first-line *Helicobacter pylori* eradication treatment: a multi-central, randomized, controlled clinical study. *Zhonghua Yi Xue Za Zhi* 2010;90:79-82.
18. Ching SS, Sabanathan S, Jenkinson LR. Treatment of *Helicobacter pylori* in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. *World J Gastroenterol* 2008;14:3855-60.
19. Choi HS, Chun HJ, Park SH, et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for *Helicobacter pylori* infection. *World J Gastroenterol* 2012;18:2377-82.
20. Choi KH, Chung WC, Lee KM, et al. Efficacy of levofloxacin and rifaximin based quadruple therapy in *Helicobacter pylori* associated gastroduodenal disease: a double-blind, randomized controlled trial. *J Korean Med Sci* 2011;26:785-90.
21. Choi WH, Park DI, Oh SJ, et al. Effectiveness of 10 day-sequential therapy for *Helicobacter pylori* eradication in Korea. *Korean J Gastroenterol* 2008;51:280-4.
22. Chung JW, Jung YK, Kim YJ, et al. Ten-day sequential versus triple therapy for *Helicobacter pylori* eradication: a prospective, open-label, randomized trial. *J Gastroenterol Hepatol* 2012;27:1675-80.
23. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of *Saccharomyces boulardii* in the 14-day triple anti-*Helicobacter pylori* therapy: a prospective randomized placebo-controlled double-blind study. *Helicobacter* 2007;12:309-16.
24. Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, et al. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line *Helicobacter pylori* eradication: a single-blind randomized clinical trial. *J Antimicrob Chemother* 2012;67:2254-9.
25. Daghighzadeh H, Emami MH, Karimi S, Raeisi M. One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for *Helicobacter pylori* infection in Iran. *J Gastroenterol Hepatol* 2007;22:1399-403.
26. Dal Bo' N, Di Mario F, Battaglia G, et al. Low dose of clarithromycin in triple therapy for the eradication of *Helicobacter pylori*: one or two weeks? *J Gastroenterol Hepatol* 1998;13:288-93.
27. Dammann HG, Fölsch UR, Hahn EG, et al. Eradication of *H. pylori* with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. *Helicobacter* 2000;5:41-51.
28. De Francesco V, Zullo A, Hassan C, et al. The prolongation of triple therapy for *Helicobacter pylori* does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. *Dig Liver Dis* 2004;36:322-6.
29. De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for *Helicobacter pylori* does not share the risk factors of triple therapy failure. *Aliment Pharmacol Ther* 2004;19:407-14.
30. Deguchi R, Nakaminami H, Rimbara E, et al. Effect of pretreatment with *Lactobacillus gasseri* OLL2716 on first-line *Helicobacter pylori* eradication therapy. *J Gastroenterol Hepatol* 2012;27:888-92.
31. Du YQ, Su T, Fan JG, et al. Adjuvant probiotics improve the eradication effect of triple therapy for

- Helicobacter pylori infection. *World J Gastroenterol* 2012;18:6302-7.
32. Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. *Helicobacter* 2012;17:43-8.
 33. Fakheri HT, MoloudFakhri, Shahmohammadi S. Efficacy of short-duration Furazolidone in two different quadruple regimens for H. pylori eradication. *Pak J Med Sci* 2011;27:887-91.
 34. Fallone CA, Barkun AN, Szilagyi A, et al. Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada. *Can J Gastroenterol* 2013;27:397-402.
 35. Farup PG, Tholfsen J, Wettrenus S, Torp R, Høie O, Lange OJ. Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. *Scand J Gastroenterol* 2002;37:1374-9.
 36. Filipec Kanizaj T, Katicic M, Skurla B, Ticak M, Plecko V, Kalenic S. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. *Helicobacter* 2009;14:29-35.
 37. Francavilla R, Polimeno L, Demichina A, et al. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. *J Clin Gastroenterol* 2014;48:407-13.
 38. Gao XZ, Qiao XL, Song WC, Wang XF, Liu F. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. *World J Gastroenterol* 2010;16:4357-62.
 39. Garza González E, Giasi González E, Martínez Vázquez MA, et al. Helicobacter pylori eradication and its relation to antibiotic resistance and CYP2C19 status. *Rev Esp Enferm Dig* 2007;99:71-5.
 40. Georgopoulos S, Papastergiou V, Xirouchakis E, et al. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. *J Clin Gastroenterol* 2013;47:228-32.
 41. Gisbert JP, Carpio D, Marcos S, Gisbert JL, García Grávalos R, Pajares JM. One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. *Eur J Gastroenterol Hepatol* 2000;12:489-95.
 42. Gisbert JP, Domínguez-Muñoz A, Domínguez-Martín A, Gisbert JL, Marcos S. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? *Am J Gastroenterol* 2005;100:1935-40.
 43. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. *Eur J Gastroenterol Hepatol* 2001;13:1303-7.
 44. Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. *World J Gastrointest Pharmacol Ther* 2013;4:23-7.
 45. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. *Lancet* 2011;378:507-14.
 46. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. *World J Gastroenterol* 2004;10:668-71.

47. Hu FL, Cheng H, Zhang XZ, et al. Jinghuaweikang capsules combined with triple therapy in the treatment of *Helicobacter pylori* associated gastritis and duodenal ulcer and analysis of antibiotic resistance: a multicenter, randomized, controlled, clinical study. *Zhonghua Yi Xue Za Zhi* 2012;92:679-84.
48. Hu SQ, Zhang M. A 10-day sequential therapy for *Helicobacter pylori*-infected patients: An analysis of 39 cases. *World Chin J Dig* 2009;17:1693-5.
49. Huang YK, Wu MC, Wang SS, et al. Lansoprazole-based sequential and concomitant therapy for the first-line *Helicobacter pylori* eradication. *J Dig Dis* 2012;13:232-8.
50. Hung IF, Chan P, Leung S, et al. Clarithromycin-amoxicillin-containing triple therapy: a valid empirical first-line treatment for *Helicobacter pylori* eradication in Hong Kong? *Helicobacter* 2009;14:505-11.
51. Hurenkamp GJ, Van Der Ende A, Grundmeijer HG, Tytgat GN, Van Der Hulst RW. Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate *Helicobacter pylori* infection in patients with ulcer disease. *Aliment Pharmacol Ther* 2000;14:1065-70.
52. Iacopini F, Crispino P, Paoluzi OA, et al. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for *Helicobacter pylori* eradication. *Dig Liver Dis* 2005;37:571-6.
53. Jang HJ, Choi MH, Kim YS, et al. Effectiveness of triple therapy and quadruple therapy for *Helicobacter pylori* eradication. *Korean J Gastroenterol* 2005;46:368-72.
54. Javid G, Zargar SA, Bhat K, et al. Efficacy and safety of sequential therapy versus standard triple therapy in *Helicobacter pylori* eradication in Kashmir India: a randomized comparative trial. *Indian J Gastroenterol* 2013;32:190-4.
55. Jiang YA, Ou XL, Wang JN. Efficacy of *Bacillus licheniformis* combined with PPI triple therapy in eradication of *Helicobacter pylori*. *World Chin J Dig* 2013;21:840-4.
56. Karatapanis S, Georgopoulos SD, Papastergiou V, et al. "7, 10 and 14-days rabeprazole-based standard triple therapies for *H. pylori* eradication: are they still effective? A randomized trial". *Acta Gastroenterol Belg* 2011;74:407-12.
57. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for *Helicobacter pylori* eradication: The QUADRATE Study. *Gastroenterology* 2002;123:1763-9.
58. Keum B, Lee SW, Kim SY, et al. Comparison of *Helicobacter pylori* eradication rate according to different PPI-based triple therapy--omeprazole, rabeprazole, esomeprazole and lansoprazole--. *Korean J Gastroenterol* 2005;46:433-9.
59. Kiliç ZM, Köksal AS, Cakal B, et al. Moxifloxacin plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for *Helicobacter pylori* infection. *Dig Dis Sci* 2008;53:3133-7.
60. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for *Helicobacter pylori* eradication: neither treatment duration provides acceptable eradication rate in Korea. *Helicobacter* 2007;12:31-5.
61. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for *Helicobacter pylori* eradication. *Helicobacter* 2008;13:261-8.
62. Kim N, Park SH, Seo GS, et al. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for *Helicobacter pylori* eradication in Korea. *Helicobacter* 2008;13:542-9.

63. Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for *Helicobacter pylori* in Korea. *Aliment Pharmacol Ther* 2011;34:1098-105.
64. Kiyota K, Habu Y, Sugano Y, et al. Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with *Helicobacter pylori* infection: results of a randomized controlled trial. *J Gastroenterol* 1999;34 Suppl 11:76-9.
65. Lahbabi M, Alaoui S, El Rhazi K, et al. Sequential therapy versus standard triple-drug therapy for *Helicobacter pylori* eradication: result of the HPFEZ randomised study. *Clin Res Hepatol Gastroenterol* 2013;37:416-21.
66. Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther* 1996;10:1029-33.
67. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biscaltrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of *Helicobacter pylori* in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. *Am J Gastroenterol* 2003;98:562-7.
68. Liang Z, Quan H, Xu G, Yu A. Follow-up study of 10-day sequential therapy on eradication of *Helicobacter pylori*. *Chin J Gastroenterol* 2010;15:483-5.
69. Liao J, Zheng Q, Liang X, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. *Helicobacter* 2013;18:373-7.
70. Lim JH, Lee DH, Choi C, et al. Clinical outcomes of two-week sequential and concomitant therapies for *Helicobacter pylori* eradication: a randomized pilot study. *Helicobacter* 2013;18:180-6.
71. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of *Helicobacter pylori*: a multicentre, open-label, randomised trial. *Lancet* 2013;381:205-13.
72. Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for *Helicobacter pylori* infection: a randomised comparative trial with crossover design. *Gut* 2010;59:572-8.
73. Liu KS, Hung IF, Seto WK, et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for *Helicobacter pylori* in Chinese patients: an open label, randomised, crossover trial. *Gut* 2014;63:1410-5.
74. Louw JA, van Rensburg CJ, Hanslo D, Grundlings HD, Girdwood AH, Marks IN. Two-week course of pantoprazole combined with 1 week of amoxicillin and clarithromycin is effective in *Helicobacter pylori* eradication and duodenal ulcer healing. *Aliment Pharmacol Ther* 1998;12:545-50.
75. Louw JA, Van Rensburg CJ, Moola S, Kotze D, Marks IN. *Helicobacter pylori* eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxicillin and clarithromycin. *Aliment Pharmacol Ther* 1998;12:881-5.
76. Ma CX, Peng GL, Zhao YK, Zhang XY, Zhan LY. Treatment outcomes of functional dyspepsia patients with *Helicobacter pylori* infection: a comparison between sequential treatment regimen and conventional triple therapy. *Acad J Sec Mil Med Univ* 2008;29:908-11.
77. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi Porro G. Do some patients with *Helicobacter pylori* infection benefit from an extension to 2 weeks of a proton pump

- inhibitor-based triple eradication therapy? *Am J Gastroenterol* 2001;96:359-66.
78. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet* 2011;377:905-13.
 79. Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. *Eur J Gastroenterol Hepatol* 2002;14:1237-43.
 80. Mao HV, Lak BV, Long T, et al. Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer. *Aliment Pharmacol Ther* 2000;14:97-101.
 81. McNicholl AG, Marin AC, Molina-Infante J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. *Gut* 2014;63:244-9.
 82. Mirbagheri SA, Hasibi M, Abouzari M, Rashidi A. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. *World J Gastroenterol* 2006;12:4888-91.
 83. Moayyedi P, Langworthy H, Shanahan K, et al. Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. *Helicobacter* 1996;1:71-4.
 84. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. *Helicobacter* 2012;17:269-76.
 85. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2010;31:1077-84.
 86. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. *Gastroenterology* 2013;145:121-28 e1.
 87. Morse AL, Goodman KJ, Munday R, et al. A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North. *Can J Gastroenterol* 2013;27:701-6.
 88. Multiple Center Study Group in Beijing Area, China. Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study. *Zhonghua Yi Xue Za Zhi* 2004;84:1161-5.
 89. Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study. *Aliment Pharmacol Ther* 2005;21:1263-72.
 90. Nasa M, Choksey A, Phadke A, Sawant P. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study. *Indian J Gastroenterol* 2013;32:392-6.
 91. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. *Aliment*

- Pharmacol Ther* 2004;20:1181-8.
92. Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for *Helicobacter pylori* eradication. *Am J Gastroenterol* 2006;101:1985-90.
 93. Oh HS, Lee DH, Seo JY, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. *J Gastroenterol Hepatol* 2012;27:504-9.
 94. Özdil K, Çalhan T, Şahin A, et al. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for *Helicobacter pylori* eradication. *Hepatogastroenterology* 2011;58:1148-52.
 95. Pai CG, Thomas CP, Biswas A, Rao S, Ramnarayan K. Quadruple therapy for initial eradication of *Helicobacter pylori* in peptic ulcer: comparison with triple therapy. *Indian J Gastroenterol* 2003;22:85-7.
 96. Palmas F, Pellicano R, Massimetti E, Berrutti M, Fagoonee S, Rizzetto M. Eradication of *Helicobacter pylori* infection with proton pump inhibitor-based triple therapy. A randomised study. *Panminerva Med* 2002;44:145-7.
 97. Paoluzi OA, Visconti E, Andrei F, et al. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating *Helicobacter pylori* infection: a randomized controlled study on efficacy and tolerability. *J Clin Gastroenterol* 2010;44:261-6.
 98. Paoluzi P, Iacopini F, Crispino P, et al. 2-week triple therapy for *Helicobacter pylori* infection is better than 1-week in clinical practice: a large prospective single-center randomized study. *Helicobacter* 2006;11:562-8.
 99. Park HG, Jung MK, Jung JT, et al. Randomised clinical trial: Comparative study of 10-day sequential therapy with 7-day standard triple therapy for *Helicobacter pylori* infection in naïve patients. *Aliment Pharmacol Ther* 2012;35:56-65.
 100. Park SK, Park DI, Choi JS, et al. The effect of probiotics on *Helicobacter pylori* eradication. *Hepatogastroenterology* 2007;54:2032-6.
 101. Qian J, Ye F, Zhang J, et al. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for *Helicobacter pylori* eradication in China. *Helicobacter* 2012;17:478-85.
 102. Riquelme A, Soza A, Pedreros C, et al. Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. *World J Gastroenterol* 2007;13:2967-72.
 103. Robles-Jara C, Robles-Medrandá C, Moncayo M, Landivar B, Parrales J. Is a 7-day *Helicobacter pylori* treatment enough for eradication and inactivation of gastric inflammatory activity? *World J Gastroenterol* 2008;14:2838-43.
 104. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for *Helicobacter pylori* eradication in Iran: a prospective randomized trial. *Helicobacter* 2013;18:129-34.
 105. Savarino V, Zentilin P, Bisso G, et al. Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 1999;13:43-7.
 106. Savarino V, Zentilin P, Pivari M, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against *Helicobacter pylori*. *Aliment Pharmacol Ther* 2000;14:893-900.
 107. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. *Helicobacter pylori*

- eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. *Can J Gastroenterol* 2006;20:113-7.
108. Scaccianoce G, Zullo A, Hassan C, et al. Triple therapies plus different probiotics for *Helicobacter pylori* eradication. *Eur Rev Med Pharmacol Sci* 2008;12:251-6.
 109. Seddik H, Ahid S, El Adioui T, et al. Sequential therapy versus standard triple-drug therapy for *Helicobacter pylori* eradication: a prospective randomized study. *Eur J Clin Pharmacol* 2013;69:1709-15.
 110. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with *Lactobacillus*- and *Bifidobacterium*-containing yogurt on triple therapy for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2002;16:1669-75.
 111. Sokwala A, Shah MV, Devani S, Yonga G. *Helicobacter pylori* eradication: A randomised comparative trial of 7-day versus 14-day triple therapy. *S Afr Med J* 2012;102:368-71.
 112. Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of *Helicobacter pylori*. *Helicobacter* 2010;15:206-13.
 113. Songür Y, Senol A, Balkarli A, Baştürk A, Cerçi S. Triple or quadruple tetracycline-based therapies versus standard triple treatment for *Helicobacter pylori* treatment. *Am J Med Sci* 2009;338:50-3.
 114. Spinzi GC, Boni F, Bortoli A, et al. Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of *Helicobacter pylori* in duodenal ulcer: a multicentre, randomized, single-blind study. *Aliment Pharmacol Ther* 2000;14:325-30.
 115. Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial *Helicobacter pylori* eradication. *Helicobacter* 2010;15:233-8.
 116. Sung JJ, Leung WK, Ling TK, et al. One-week use of ranitidine bismuth citrate, amoxicillin and clarithromycin for the treatment of *Helicobacter pylori*-related duodenal ulcer. *Aliment Pharmacol Ther* 1998;12:725-30.
 117. Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of *Helicobacter pylori*: a randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients. *Dig Dis Sci* 2009;54:599-603.
 118. Telaku S, Manxhuka-Kerliu S, Kraja B, Qirjako G, Prifti S, Fejza H. The efficacy of levofloxacin-based triple therapy for first-line *Helicobacter pylori* eradication. *Med Arch* 2013;67:348-50.
 119. Ungan M, Kulaçoğlu H, Kayhan B. Cure rates obtained with five different *Helicobacter pylori* eradication protocols in patients with duodenal ulcer: A prospective, open-label, randomized study in a primary care setting in Turkey. *Curr Ther Res Clin Exp* 2001;62:462-72.
 120. Uygun A, Kadayifci A, Polat Z, et al. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for *Helicobacter pylori*. *Turk J Gastroenterol* 2012;23:8-13.
 121. Uygun A, Kadayifci A, Safali M, Ilgan S, Bagci S. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for *Helicobacter pylori*. *J Dig Dis* 2007;8:211-5.
 122. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for *Helicobacter pylori* eradication: a randomized trial. *Ann Intern Med* 2007;146:556-63.
 123. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for *Helicobacter pylori* in the United States. *Aliment Pharmacol Ther* 2004;20:99-107.

124. Valooran GJ, Kate V, Jagdish S, Basu D. Sequential therapy versus standard triple drug therapy for eradication of *Helicobacter pylori* in patients with perforated duodenal ulcer following simple closure. *Scand J Gastroenterol* 2011;46:1045-50.
125. Wang PW, Jiang HQ, Jing DD. A randomized open parallel controlled multi-center study of ranitidine bismuth citrate (RBC) or esomeprazole (EMO) in the triple therapies for eradication of *Helicobacter pylori* infection. *Chin J New Drugs* 2008;17:515-7.
126. Wong BC, Wong WM, Wang WH, et al. One-week ranitidine bismuth citrate-based triple therapy for the eradication of *Helicobacter pylori* in Hong Kong with high prevalence of metronidazole resistance. *Aliment Pharmacol Ther* 2001;15:403-9.
127. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of *H pylori* infection. *Clin Gastroenterol Hepatol* 2010;8:36-41 e1.
128. Wu GL, Lan Y, Zhang XJ. Sequential therapy versus standard triple therapy for *Helicobacter pylori* eradication. *World Chin J Dig* 2011;19:3100-3.
129. Xu MH, Zhang GY, Li CJ. Efficacy of bismuth-based quadruple therapy as first-line treatment for *Helicobacter pylori* infection. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 2011;40:327-31.
130. Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line *Helicobacter pylori* eradication: A randomized study in Japan. *World J Gastrointest Pharmacol Ther* 2012;3:1-6.
131. Yaşar B, Abut E, Kayadibi H, et al. Efficacy of probiotics in *Helicobacter pylori* eradication therapy. *Turk J Gastroenterol* 2010;21:212-7.
132. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for *Helicobacter pylori* eradication: the HYPER Study. *Gut* 2007;56:475-9.
133. Zhang XM, Zhang ZY. Efficacy and safety of levofloxacin-based triple regimen and bismuth-based quadruple regimen in the management of *Helicobacter pylori* infection. *World World Chin J Dig* 2010;18:1951-3.
134. Zhao QX, Huang DY. Efficacy of tinidazole-containing sequential therapy in the eradication of *Helicobacter pylori* infection. *World Chin J Dig* 2009;17:3666-9.
135. Zheng Q, Chen WJ, Lu H, Sun QJ, Xiao SD. Comparison of the efficacy of triple versus quadruple therapy on the eradication of *Helicobacter pylori* and antibiotic resistance. *J Dig Dis* 2010;11:313-8.
136. Zheng Q, Dai J, Li X, Lu H, Xiao S. Comparison of the efficacy of pantoprazole-based triple therapy versus quadruple therapy in the treatment of *Helicobacter pylori* infection: A single-center, randomized, open and parallel-controlled study. *Chin J Gastroenterol* 2009;14:8-11.
137. Zheng Q, Pan Y, Zhang L, Xiao S. Comparison of efficacy of 7-day rabeprazole-based triple therapy versus quadruple therapy for treatment of *Helicobacter pylori* infection. *Chin J Gastroenterol* 2006;11:645-7.
138. Zhou YQ, Xu L, Wang BF, et al. Modified Sequential Therapy Regimen versus Conventional Triple Therapy for *Helicobacter Pylori* Eradication in Duodenal Ulcer Patients in China: A Multicenter Clinical Comparative Study. *Gastroenterol Res Pract* 2012;2012:405425.
139. Ziemniak W. Efficacy of *Helicobacter pylori* eradication taking into account its resistance to antibiotics. *J Physiol Pharmacol* 2006;57 Suppl 3:123-41.
140. Zojaji H, Ghobakhlou M, Rajabalinia H, et al. The efficacy and safety of adding the probiotic

- Saccharomyces boulardii to standard triple therapy for eradication of H. pylori: a randomized controlled trial. *Gastroenterol Hepatol Bed Bench* 2013;6(suppl 1):S99-s104.
141. Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. *Aliment Pharmacol Ther* 2005;21:1419-24.
142. Zullo A, Scaccianoce G, De Francesco V, et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study. *Clin Res Hepatol Gastroenterol* 2013;37:647-50.
143. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. *Aliment Pharmacol Ther* 2003;17:719-26.